Mountain Valley MD Holdings (MVMD) (OTCQX: MVMDF) has announced the successful completion of its pre-clinical pharmacokinetic study. The pre-clinical pharmacokinetic study – IM032, was done on male beagle dogs by comparing the intramuscular (IM) and subcutaneous (SC) dosing of SoluvecTM 1% with oral administration of commercially available ivermectin. A third-party contract research organization conducted the pre-clinical study.
The results of the pre-clinical canine trial tests demonstrated that:
Soluvec, if administered IM and SC at the same dose level (300 mg/kg) as the reference product oral ivermectin, will result in mean maximum plasma concentrations of 2.6 ...Read The Full Article On StreetSignals.com
Get the latest stock market news on StreetSignals . Follow public companies and get free stock research reports and stock market analysis data and stock tips.
All content provided by StreetSignals is subject to our Terms Of Use and Disclaimer .
For further details see:
Mountain Valley MD Holdings Completes Pre-clinical Pharmacokinetic Study for Soluvec